-

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bright Health Group, Inc. (BHG)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 7, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Bright Health Group, Inc. (“Bright Health” or the “Company”) (NYSE: BHG): (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s June 2021 initial public offering (“IPO” or the “Offering”); (b) and/or securities between June 24, 2021 and November 10, 2021, inclusive (the “Class Period”).

If you suffered a loss on your Bright Health investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/bright-health-group-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

In June 2021, Bright Health completed its IPO, selling approximately 51 million shares of common stock for $18.00 per share.

On November 11, 2021, Bright Health reported its third quarter financial results, revealing earnings per share (“EPS”) of -$0.48 as calculated under U.S. generally accepted accounting principles (“GAAP”), missing consensus estimates by $0.31. The Company also reported a sharp rise in the Company’s medical cost ratio (“MCR”), advising investors that its MCR “for the third quarter of 2021 was 103.0%, including a 540 basis point unfavorable impact from COVID-19 related costs and a 900 basis point unfavorable impact primarily from a cumulative reduction in premium revenue due to an inability to capture risk adjustment on newly added lives.”

On this news, Bright Health’s stock fell $2.36, or 32%, to close at $4.94 per share on November 11, 2021, significantly below the IPO price.

The complaint filed in this class action alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Bright Health had overstated its post-IPO business and financial prospects; (2) the Company was ill-equipped to handle the impact of COVID-19-related costs; (3) the Company was experiencing a decline in premium revenue because of a failure to capture risk adjustment on newly added lives; (4) all the foregoing was reasonably likely to have a material negative impact on Bright Health's business and financial condition; and (5) as a result, Defendants' positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Bright Health securities during the Class Period, you may move the Court no later than March 7, 2022 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Glancy Prongay & Murray LLP

NYSE:BHG

Release Versions

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

More News From Glancy Prongay & Murray LLP

Deadline Alert: Lennar Corporation Investors Have Until January 11, 2027 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

LOS ANGELES--(BUSINESS WIRE)--Investors in Lennar Corporation ("Lennar" or the "Company") (NYSE: LEN) have until January 11, 2027 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Lennar Corporation securities between February 7, 2025 and October 2, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline. The Lennar Corporation case...

Securities Fraud Class Action Filed Against Nuscale Power Corporation: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

LOS ANGELES--(BUSINESS WIRE)--A securities fraud class action lawsuit has been filed against Nuscale Power Corporation ("Nuscale" or the "Company") (NYSE: SMR) on behalf of investors who purchased or otherwise acquired the Company's securities between February 27, 2026 and September 10, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced the filing. The Nuscale Power Corporation case, Chiu-Yueh Chang v. NuScale Power Corporation et al., was filed on November 11, 202...

Lost Money on Evolution Metals & Technologies Corp. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 25.78% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Evolution Metals & Technologies Corp. ("Evolution Metals" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Evolution Metals & Technologies Corp. (NASDAQ: EMAT) investors into whether the Company may have violated the federal securities laws.Investors who lost money on Evolution Metals & Technologies Co...
Back to Newsroom